BIOMARIN PHARMACEUTICAL INC Gain (Loss) on Derivative Instruments, Net, Pretax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Gain (Loss) on Derivative Instruments, Net, Pretax of $12.82 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-04-29.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2019-04-29
- BIOMARIN PHARMACEUTICAL INC gain (loss) on derivative instruments, net, pretax for the quarter ending 2019-03-31 was $12.82M.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month |
|---|---|
| 2019-03-31 | $12.82M 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |